710001

antibody from Invitrogen Antibodies

Targeting: CCL5 D17S136E, MGC17164, RANTES, SCYA5, SISd, TCP228

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

710001

Provider

Invitrogen Antibodies

Product name

CCL5 (RANTES) Recombinant Polyclonal Antibody (25HCLC)

Antibody type

Polyclonal

Antigen

Other

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Antibody clone number

25HCLC

Vial size

100 µg

Concentration

0.5 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.

Li X, Fang T, Xu S, Jin P, Zhou D, Wang Z, Li H, Yang Z, Chen G, Zheng X, Xia Y, Wei X, Zhang Z, Yang X, Wang Y, Gao Q
NPJ precision oncology 2021 Jun 9;5(1):49

---

Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis.

Liu Y, Zhao Y, Shukha Y, Lu H, Wang L, Liu Z, Liu C, Zhao Y, Wang H, Zhao G, Liang W, Fan Y, Chang L, Yurdagul A Jr, Pattillo CB, Orr AW, Aviram M, Wen B, Garcia-Barrio MT, Zhang J, Liu W, Sun D, Hayek T, Chen YE, Rom O
Cell reports 2021 Jul 27;36(4):109420

---

DSE regulates the malignant characters of hepatocellular carcinoma cells by modulating CCL5/CCR1 axis.

Liao WC, Yen HR, Liao CK, Tseng TJ, Lan CT, Liu CH
American journal of cancer research 2019;9(2):347-362

---

NADPH Oxidase 4 Regulates Inflammation in Ischemic Heart Failure: Role of Soluble Epoxide Hydrolase.

Stevenson MD, Canugovi C, Vendrov AE, Hayami T, Bowles DE, Krause KH, Madamanchi NR, Runge MS
Antioxidants & redox signaling 2019 Jul 1;31(1):39-58

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescence analysis of CCL5/RANTES was performed using 70% confluent log phase HEK-293 cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 2% BSA for 1 hour at room temperature. The cells were labeled with CCL5/RANTES (25HCLC) Recombinant Rabbit Polyclonal Antibody (Product # 710001) at 2 µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing cytoplasmic localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 7 Olaparib induces stromal fibroblast activation in human OC tumor specimens. a Immunohistochemical detection of alpha-SMA in matched tumor specimens from patients with OC before and after administration with Ola. Scale bar, 50 um. b Quantification of alpha-SMA-positive areas in tumor specimens from OC patients. Same images were measured repeatedly. c - e Representative images and quantification of Masson's trichrome and picrosirius red staining showing that Ola administration increased the content of stromal components and collagen deposition in human OC tumor specimens. Scale bar, 50 um. Same images were measured repeatedly. f , g Representative IHC images and quantification of CCL5 and p-P65 in matched tumor specimens from patients with OC before and after administration with Ola. Scale bar, 50 um. Measures were taken from different samples ( n = 6). h Correlation analysis of CCL5 IHC scores and alpha-SMA IHC scores in matched tumor specimens from patients with OC before and after administration with Ola. i Correlation analysis of p-P65 IHC scores and CCL5 IHC scores in matched tumor specimens from patients with OC before and after administration with Ola. j Schematic representation of the effect of PARPis on human ovarian stromal fibroblasts. Data are expressed as mean +- s.e.m., * p < 0.05; ** p < 0.01; *** p < 0.001.